

Neurotrophins and neurodegeneration

D. Dawbarn and S. J. Allen

University of Bristol, Bristol Royal Infirmary, Bristol, UK

D. Dawbarn and S. J. Allen (2003) *Neuropathology and Applied Neurobiology* 29, 211–230

Neurotrophins and neurodegeneration

There is growing evidence that reduced neurotrophic support is a significant factor in the pathogenesis of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). In this review we discuss the structure and functions of neurotrophins such as nerve growth factor, and the role of these proteins and their tyrosine kinase (Trk) receptors in the aetiology and therapy of such diseases. Neurotrophins regulate development and the maintenance of the vertebrate nervous system. In the mature nervous system they affect neuronal survival and also influence synaptic function and plasticity. The neurotrophins are able to bind to two different receptors: all bind to a common receptor p75^{NTR}, and each also binds to one of a family of Trk receptors. By dimerization of the Trk recep-

tors, and subsequent transphosphorylation of the intracellular kinase domain, signalling pathways are activated. We discuss here the structure and function of the neurotrophins and how they have been, or may be, used therapeutically in AD, PD, Huntington's diseases, ALS and peripheral neuropathy. Neurotrophins are central to many aspects of nervous system function. However they have not truly fulfilled their therapeutic potential in clinical trials because of the difficulties of protein delivery and pharmacokinetics in the nervous system. With the recent elucidation of the structure of the neurotrophins bound to their receptors it will now be possible, using a combination of *in silico* technology and novel screening techniques, to develop small molecule mimetics with much improved pharmacotherapeutic profiles.

Keywords: ALS, Alzheimer's, Huntington's, mimetics, neuropathy, neurotrophins, NGF, Parkinson's

The neurotrophins and their receptors

Over the last two decades much progress has been made in understanding the relationship between neurotrophins, their receptors and neurodegenerative diseases. In particular nerve growth factor (NGF) and its receptor TrkA have a prominent role in both the aetiology and the treatment of Alzheimer's disease (AD). In Huntington's disease the mutant protein huntingtin leads to a down-regulation of brain-derived neurotrophic factor (BDNF) in the basal ganglia leading to neuronal loss, opening up the possibility of BDNF therapy. Moreover, startling clinical results have been found using intraparenchymal injection of a related neurotrophic factor, glial-derived neurotrophic factor (GDNF), for the treatment of Parkinson's disease (PD). This

review discusses in depth the involvement of the neurotrophins in neurodegenerative diseases.

Neurotrophins, a historical perspective

The first neurotrophin to be discovered was NGF. In 1948 it was shown that, when fragments of a mouse sarcoma were grafted into the body wall of chick embryos, the sensory nerve fibres from the chick dorsal root ganglion (DRG) penetrated into the sarcoma [29]. Later sympathetic fibres were also shown to penetrate the sarcoma, and the sympathetic ganglia innervating the tumour increased in volume [120]. Subsequent purification studies led to the isolation of a nucleoprotein fraction with nerve growth-promoting activities. A systemic search of mammalian tissues showed that male mouse salivary glands contained relatively large amounts of NGF [42]. Further work established that NGF is released by the target tissues of sympa-

Correspondence: David Dawbarn, University of Bristol, Bristol Royal Infirmary, Bristol, BS2 8HW, UK. Tel: 01179 282897, Fax: 01179 283137. E-mail: dave.dawbarn@bristol.ac.uk

thetic and sensory fibres, and is taken up by the fibres and retrogradely transported to the cell body. From this work the Neurotrophic Factor Hypothesis is developed. This proposed that a developing neurone, having extended processes into its target organ, would be in competition with other neurones for limited supplies of target-produced neurotrophic factors. Those that obtain the growth factor survive; those that do not die.

The sequencing of mouse salivary gland NGF, in 1971 [93], provided information on its primary structure but more importantly also paved the way for the cloning of the mouse and human genes. The human NGF gene is located on the short arm of chromosome 1 (1p22) [66] and codes for a polypeptide of 307 amino acids which, when the signal peptide and pro region are cleaved, gives rise to a mature protein of 118 amino acids which naturally exists as a noncovalently bound homodimer.

The neurotrophin family

In addition to NGF, another factor was purified from pig brain that demonstrated neuronal growth-promoting activities [13]; this was later called BDNF. Cloning of the gene [119] (present on human chromosome 11: 11p13 [128]) revealed close homology to NGF with 51 identical amino acids; such similarity suggested that it also existed as a homodimer. By using the contiguous regions between NGF and BDNF to design oligonucleotides for polymerase chain reaction cloning, a third related protein called neurotrophin 3 (NT-3) was cloned [59,94,127]. This is located on human chromosome 12 (12p13) [128]. Finally after an exhaustive search the last of the neurotrophin family was identified and cloned in *Xenopus* (NT-4) [80]. The equivalent human cDNA was sufficiently different from *Xenopus* NT-4 for it to be thought a separate gene and called NT-5 [19]. Subsequently it was realized that they are homologous genes and this neurotrophin is often now termed NT-4/5. NT-4/5 is present on human chromosome 19 (19q13.3) [18]. NT-6 has only been found in fish [75]. All the neurotrophins are synthesized as precursor proteins (approximately 30 kDa in size) and are cleaved to form the mature form, and all form noncovalent-linked homodimers where each monomer is approximately 13 kDa. They are all basic proteins with isoelectric points above 9.0. Because of the characteristic formation of a double loop formed by two disulphide bonds, penetrated by a third disulphide bond, they are classed as part of the Cysteine Knot Superfamily. The X-ray crystal

structures of the neurotrophins have all been elucidated and are shown in Figure 1. Shown for comparison is the structure of a related protein, GDNF, which is also a member of the Cysteine Knot Superfamily. This protein is briefly mentioned in this review because of its recent success in PD trials.

Neurotrophin receptors: identification and structure

p75^{NTR} receptor The receptors for NGF were first identified on chick sensory ganglia and DRG using receptor-binding techniques with ¹²⁵I-labelled NGF [194]. Originally this receptor was thought to be specific for NGF, although its method of signalling was unclear. It was eventually established, by analysis of the binding kinetics, that there were two receptors present: one with a dissociation constant (Kd) of approximately 10⁻¹¹ M and the other with a Kd of approximately 10⁻⁹ M. The molecular weights were subsequently determined by cross-linking experiments and found to be approximately 140 kDa and approximately 75 kDa, respectively. The lower-affinity receptor was cloned from rat [161] and human [103] and was usually referred to as p75^{NGFR}. It is now known to be a common receptor for all of the neurotrophins (p75^{NTR}) [169]. The 3.8 kb mRNA for p75^{NTR} encodes a 427 amino acid protein containing a 28 amino acid signal peptide, a single transmembrane domain and a 155 amino acid cytoplasmic domain. The gene is present on the human chromosome 17 (17q21-22) [97]. A schematic of the structure of the p75^{NTR} and that of the tyrosine kinase (Trk) receptors is given in Figure 2. The p75^{NTR} receptor was shown to be a member of the tumour necrosis superfamily of receptors [26,35] and contains a cytoplasmic 'death' domain [122], a domain known to be involved in apoptosis.

Neurotrophin binding to p75^{NTR} has been shown to affect cell survival [14] and axonal outgrowth [17,207]. Independent of Trk, the binding of neurotrophins to the p75^{NTR} receptor results in activation of NFκβ, a transcription factor [33], and c-Jun N-terminal kinase kinase [34]. Recently p75^{NTR} has been shown to interact with the Nogo receptor which is involved in myelin-associated inhibition of axonal elongation [53].

Trk receptors: discovery and structure In 1986 a human oncogene was isolated from colon carcinoma and was called *trk* (tyrosine receptor kinase) [130]. The gene consisted of a fusion between a known muscle protein, tro-

pomyosin, and a receptor kinase domain from an unknown protein. Use of the sequence of the Trk domain to screen cDNA libraries led to the identification of the proto-oncogene *trkA* [131]. The fact that the expression profile for *trkA* correlated with the location of those neurones that respond to NGF and that the size of the TrkA protein was approximately 140 kDa led to the breakthrough by Klein [107] that TrkA was the receptor for NGF. Screening of cDNA libraries had led to the identification of the related genes *trkB* [110] and *trkC* [118]. TrkB protein was shown to be a receptor for BDNF [109] and NT-4/5 [108] and

TrkC was found to be a receptor for NT-3 [118]. The protein Trk domains of TrkA, TrkB and TrkC were found to be 87% homologous at the amino acid level. TrkA, like NGF, is located on chromosome 1 (1q21–22), TrkB is on chromosome 9 (9p22.1) and TrkC is on chromosome 15 (15q25). Northern analysis using probes for *trkA*, *trkB* and *trkC* demonstrated that their expression is restricted primarily to the nervous system.

These Trk receptors form a homologous family of proteins, each comprising about 800 amino acids with half of the residues at the amino terminus forming the extracellular portion of the receptor. Examination of sequence motifs in the extracellular region of the Trk receptors showed that there are five distinct domains [180] (Figure 2). Mutational and domain-swapping




Figure 1. X-ray crystal structures of (A) NGF homodimer; (B) BDNF:NT-3 heterodimer, a recombinant protein which may not exist naturally, made for the structural determination of both proteins simultaneously [168]; (C) NT-4 homodimer; and (D) GDNF homodimer. One chain is shown in yellow, the other in blue. The disulphide bonds which form the cysteine knot motif are shown in green and are only shown for one chain for A, C and D. For B they are shown for both monomers because this comprises of two different neurotrophins. The two monomers of GDNF are connected by a disulphide bond, which is shown in red. The N-terminal amino acid for each of the chains is indicated. Note that in each case several amino acids are missing in the structures. GDNF is not a neurotrophin but is of the cysteine knot superfamily, which all share a similar overall monomer fold. NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor; NT, neurotrophin; GDNF, glial-derived neurotrophic factor.




Figure 2. Schematic representation of the p75^{NTR} and a generic tyrosine kinase receptor showing individual domains.




Figure 3. Comparison of the X-ray crystal structures of known Trk-neurotrophin complexes. α traces of the TrkB:Ig2:NT-4/5 (cyan and blue, respectively) and TrkA:Ig2:NGF (pink and red, respectively). Note that in each case the N-terminal of each neurotrophin is now fully visible and forms intimate contact with the Trk receptors. Trk, tyrosine kinase; Ig, immunoglobulin; NT, neurotrophin; NGF, nerve growth factor.

experiments suggested that the immunoglobulin (Ig)-like domains were involved in ligand binding [153]. The expression and purification of recombinant Ig domains in *Escherichia coli* allowed the determination of the dissociation constants for their ligands, the neurotrophins [95,167]. These studies conclusively showed that the Ig domains bind to the neurotrophins with similar affinity to the wild type membrane-bound receptors [95,167]. The X-ray crystal structures of TrkAIg2, TrkBIg2 and TrkCIg2 domains have been determined [167,203] but in each case, the structures generated were those of artificial strand-swapped dimers where the A strand from each monomer sits next to the B strand of the other monomer. The correct structures were generated using molecular modelling and showed that the Ig2 domains adopt an I-set fold. Subsequently the crystal structures of NGF bound to TrkAIg2, NT-4/5 bound to TrkBIg2 (Figure 3) and a model of BDNF bound to TrkBIg2 showed that the original models of the Ig2 domains were indeed correct [12,149,210].

Differential splice variants of TrkA, TrkB and TrkC, producing additional short amino acid sequences in the juxtamembrane domains of the receptors, may have effects on ligand interactions [40,182,190]. There is also differential splicing of exons coding for the intracellular portion of the TrkB and TrkC receptors. Both these receptors have forms that do not have kinase domains, the functions of which are thought to include clearance of ligand, and perhaps inhibition of dimerization thus reducing response [57].

Signalling through the Trk receptors

Binding of the neurotrophins to the Trk receptors initiates signalling cascades, by means of phosphorylation of tyrosine residues on the cytoplasmic domains of the receptors. Phosphorylation induces docking of adapter proteins with phosphotyrosine-binding or src-homology-2 motifs. These adapter proteins couple the receptors to intracellular signalling cascades, which include the phosphatidylinositol-3-kinase/Akt kinase pathway, phospholipase C γ and the Ras kinase pathway [106] ultimately leading to activation of gene expression, neuronal survival and neurite outgrowth.

Interactions of Trk and p75^{NTR}

Binding of neurotrophins to their Trk receptors causes signalling events which promote neurone survival, whereas

activation of the p75^{NTR} pathway triggers apoptosis and cell death [20]. The capacity of NT-3 to activate TrkA, and of NT-3 and NT-4/5 to activate TrkB is regulated by p75^{NTR} [21]. It is likely that neurotrophins can bind both Trk and p75^{NTR} simultaneously, and that Trk receptors and p75^{NTR} may interact with each other [20,21].

Distribution of the neurotrophins and their receptors in the brain

All of the neurotrophins show different distributions through the peripheral nervous system and central nervous system (CNS) with distinct and overlapping specificity towards subpopulations of sensory neurones of both neural crest and neural placode origin. Highest levels of BDNF mRNA, NGF mRNA and NT-3 mRNA in the adult mouse brain [91] are found in the hippocampus, with 50 times more BDNF mRNA being present than NGF mRNA. NT-3 is by far the most highly expressed in the immature CNS and expression dramatically decreases with maturation. BDNF expression is low in developing regions of the CNS and increases as these regions mature, whereas NGF expression varies during the development dependant on the region [126]. Cholinergic neurones project from the basal forebrain nucleus (nucleus basalis of Meynert, nbM) to the hippocampus and neocortex with 80–90% of the neurones in the human/primate nbM being cholinergic [137,138]. If ¹²⁵I-NGF is injected into the hippocampus or the cortex, it is taken up by the terminals of cholinergic cells and retrogradely transported back to the cell bodies in the basal forebrain [181]. Thus levels of NGF mRNA in various regions of the brain were found to correlate with the degree of basal forebrain cholinergic innervation [114] with highest levels of NGF and NGF mRNA in the hippocampus and cerebral cortex. Figure 4 shows a human basal forebrain neurone stained with anti-p75^{NTR}.

Immunohistochemical and *in situ* analysis of the distribution of p75^{NTR} in rat and primate brain [4,49,111,165] and colocalization of choline acetyltransferase (ChAT) and p75^{NTR} immunoreactivity [50,111] show that p75^{NTR} is almost exclusively located on basal forebrain cholinergic neurones. More recently, examination of the distribution of TrkA protein and mRNA in rat and human brain shows that TrkA is also expressed on basal forebrain cholinergic neurones [186,189] although there are some TrkA-positive, p75^{NTR}-negative neurones in the striatum [4,50,189]. By contrast TrkB and TrkC are much more widely distributed [36].

Alzheimer's disease

Overview of symptoms and pathogenesis

Alzheimer's disease is the most common form of dementia in the elderly. It is characterized by memory loss and confusion, together with neuropathological changes including neuronal loss, extracellular deposits of amyloid plaques and intracellular deposition of hyperphosphorylated tau ('tangles') [2]. Rarely, cases are familial, with autosomal dominance, because of mutations in the proteins amyloid precursor protein (APP), or presenilin 1 or 2 (PS1, PS2); but most cases are sporadic, of unknown aetiology, although the presence of a particular isoform of the protein apolipoprotein E, apoE4, results in an increased risk of AD in the general population. It is widely thought that pathology is related to increased production of a 4-kDa peptide called amyloid or A β , processed from APP by enzymes known as β -secretase (BACE: β site APP cleaving enzyme) and γ -secretase (associated with PS1/2) and recent evidence shows that enzymes associated with the processing of APP may be affected in sporadic AD [96,202].

The cholinergic deficit and current treatment

The earliest symptom of AD is a loss of short-term memory. This has been associated with the early and substantial decline in cholinergic function in the cortex and hippocampus [27,48,156]. The majority of the cholinergic neurones innervating the cortex and hippocampus originate from the basal forebrain nuclei including the medial septal nucleus and the nbM [137]. Lesions of the innervating cholinergic pathways or administration of anticholinergics such as scopolamine result in impaired ability to perform certain memory tasks [56,164]. Currently the only successful drug therapies for AD are acetylcholinesterase inhibitors, which inhibit the breakdown of acetylcholine and thus potentiate its action. Early trials [193] showed great improvements in patients using the anticholinesterase tacrine (Cognex). Now large multicentre studies have shown that tacrine treatment is of some benefit in some AD patients, and although not as dramatic as in the original study it is able to improve cognitive function significantly [11]. Side-effects were cause for concern, however, second-generation cholinesterase inhibitors, donepezil (Aricept), rivastigmine (ENA 713, Exelon), and galantamine (Reminyl), are better tolerated resulting in

cognitive improvement in over half the patients, often for 6–9 months or even longer.

Cholinergic cell loss in Alzheimer's disease

In AD, cholinergic cells of the basal forebrain may be either lost or atrophied, although, in general, the loss of cortical cholinergic activity far exceeds the neuronal loss in the nbM. There is a variance as to extent of loss reported, probably mainly because of age of patients, as brain samples from younger patients often show more extreme losses [3,72,87,143]. Analysis of cholinergic cells in brains from severely demented patients who died in their late 70s and 80s, visualized using anti-p75^{NTR}, showed only moderate cell loss in most areas of the nbM [3]. Dementia (Kew) score correlated best with accumulated neuronal losses in the intermediate and posterior regions, areas reported by others as most affected [143,201]. In normal and AD basal forebrain, similar amounts of mRNA for p75^{NTR} were found by Northern blotting [72] and with ligand binding studies of p75^{NTR} [143,201]; although studies examining the number of TrkA positively staining cells in AD basal forebrain have generally shown a marked reduction in AD [25,145].

It has been suggested that the observed degeneration of these cholinergic cells in AD may be caused by reduced trophic support; that is, a lack of production of NGF in the cerebral cortex and hippocampus. However, measurements of the content of NGF protein in brain have shown nonsignificant [5] or significant [47] increases, not decreases as expected, in cerebral cortex in AD. Recent evidence suggests that the situation is not quite so straightforward. By use of Western blotting, pro-NGF rather than mature NGF was seen to be doubled in AD parietal cortex [61]. Thus the balance between pro-NGF and mature NGF may be critical [36]. In addition, it is possible that there is a dysfunction in retrograde transport of NGF from the target tissues to the cell bodies. Support for this hypothesis comes from a study that shows defective transport in NGF in a model of Down's syndrome or trisomy 21. Down's syndrome invariably results in the symptoms and pathology of AD by the fourth decade of life. This is thought to be caused by the presence of an extra copy of the APP gene in Down's syndrome patients, possibly leading to an increased amyloid burden. In a study using a mouse model of this disorder (trisomy 16), there was no retrograde transport of radio-iodinated NGF from the hippocampus to the septum in trisomic mice, compared with almost complete transport in wild-type littermates [45]. If this were also true of

AD, it would explain why NGF levels are not diminished in target areas of the cholinergic basal forebrain cells. In addition, we know that NGF content, whilst not reduced in the cerebral cortex and hippocampus, is decreased in the basal forebrain [144].

NGF restores cholinergic function

Numerous studies have shown that administration of NGF to the basal forebrain cholinergic neurones *in vitro* results in increased survival and up-regulation of ChAT (the enzyme involved in synthesis of acetylcholine) activity [71,83–85,88,132]. This is also true *in vivo*. Lesion of the connection between the septum and the hippocampus, involving severing of the fimbria-fornix in rats, prevents the retrograde transport of NGF down cholinergic fibres to the cell bodies, resulting in cholinergic cell atrophy. Intracerebroventricular (icv) administration of NGF has been shown to abolish this degeneration [68,82,86,116,213] and the cognitive deficits arising from these lesions [129,212,213]. In addition, a subpopulation of aged rats which perform poorly in the Morris water maze and have reduced cholinergic function is able to function normally after icv infusion of NGF [63–65].

Clinical trials with NGF protein

Intracerebroventricular administration of NGF In clinical trials in the early 90s, three AD patients in Sweden were administered mouse NGF icv [104,151] continuously for up to 3 months. Two of these patients were given up to a total of 6.6 mg. The results were different in each patient. In general, some improvements were seen in a few of the cognitive tests: in one patient cortical blood flow was increased, and another showed increased glucose metabolism; ¹¹C nicotine binding in the cortex was increased in the two patients given the higher dose. Nevertheless, there were side-effects. The two patients with higher doses showed loss of weight and appetite, and all three patients reported pain. These symptoms all ceased when the NGF infusion was stopped. However, in addition, a dose-related Schwann cell hyperplasia after icv administration of rhNGF in rats [52,214] and primates [214] has been observed. Histological examination showed atypical hyperplastic tissue, attached to the dorsal and lateral surface of the medulla and the spinal cord. This hyperplasia was reversible: in the Day-Lollini study [52] it was significantly reduced after 8 weeks and completely abolished after 52 weeks. These

studies suggest that infusion with icv administration of NGF will probably result in a similar hyperplasia in man and, although probably reversible and nonmalignant, it may be partly responsible for pain. It is also worthy of note that this is caused by the presence of p75^{NTR} receptors, not TrkA, because these hyperplastic cells were found to be immunoreactive for p75^{NTR} but not TrkA. Thus it may be better to administer NGF by some other route to avoid side-effects associated with icv administration.

Other routes of administration Studies have shown that retroviral transfected fibroblasts, expressing NGF, rescue cholinergic neurones after a fimbria fornix lesion in the rat [23]. In addition, aged rhesus monkeys, with atrophy in the cholinergic basal forebrain, injected with NGF-expressing fibroblasts into the tissue adjacent to the basal forebrain, restored numbers of ChAT-positive subcortical neurones after 3 months [185]. In April 2001, a 60-year-old Caucasian woman, in the early stages of AD, was surgically implanted with her own modified fibroblasts, transfected with a virus-expressing NGF. The patient received five implants of modified cells near the nbM. We await results of this trial by researchers at the University of California at San Diego and the Salk Institute for Biological Sciences. In addition, reports have shown that following injection of ¹²⁵I-NGF into the olfactory bulb of rats, radio-labelled NGF was found to be retrogradely transported specifically to basal forebrain cholinergic nuclei [7]. Similarly it has been shown that radio-labelled NGF can be transported into the brain following administration as nose drops [39,197]. This may be a feasible mode of administration for the future.

A link between NGF and the neuropathology of Alzheimer's disease

In the phenotypes of knockouts of both NGF and TrkA [46,184] there are large reductions in ChAT immunoreactivity in the basal forebrain and loss of cholinesterase activity in both the hippocampal and cortical issues. Mice that are heterozygous for the NGF deletion have deficits in spatial memory function in the Morris water maze [37,38] that correlate with losses in ChAT-positive basal forebrain neurones.

Recently, a transgenic mouse (AD11) has been established which produces antibodies to NGF [32,175]. These antibodies accumulate throughout the adult life of the animal thus obviating the developmental problems

associated with the NGF knockout. The mice acquire an age-dependent pathology reminiscent of human AD, including amyloid plaques, and hyperphosphorylated tau in cortical and hippocampal neurones [32]. In addition they display extensive cortical cell loss, cholinergic deficit in the basal forebrain and behavioural deficits. Recently the effects of intranasal administration of NGF and intraparenchymal injection of galantamine have been studied in these mice [31]. A variety of regimes at 2, 6 and 6.5 months of age were assessed with striking results. Administration of NGF (1.2–12 µg on alternate days) or galantamine (3.5 mg/kg daily) completely restored the number of ChAT-immunopositive neurones to normal values. In addition, NGF reversed deposition of hyperphosphorylated tau in 2- and 6-month-old and markedly reduced amyloid plaques in the 6- and 6.5-month-old rats. It had no effect, however, on deposited APP in cerebral vessels. By contrast galantamine removed APP deposition but had no effect on hyperphosphorylated tau. It did, however, remove amyloid plaques almost as effectively as NGF. Surprisingly the acetylcholinesterase inhibitors tacrine and physostigmine had no effect on any of these parameters and it was suggested by the authors that it is the nicotinic receptor modulating effects of galantamine that are important here. These studies suggest that it is a lack of available NGF that begins the process of plaque and tangle formation. It seems that galantamine is able to reverse the plaque deposition but not tangle formation. In the future it will be interesting to note if AD patients, on a regime of galantamine, have lower plaque numbers than expected.

BDNF in Alzheimer's disease

In addition to the link between NGF and AD there is some evidence to implicate changes in BDNF and TrkB in the disease process. Firstly, BDNF mRNA has been reported as decreased in AD hippocampal samples by *in situ* hybridization [157], and by immunocytochemical techniques; BDNF protein levels are reported as reduced in neurones of the hippocampus and temporal cortex [44]. There is also some evidence to suggest a change in the TrkB receptor. Immunopositive, truncated (95 kDa) TrkB receptors are reported as present in amyloid plaques of the hippocampus [43]. In the basal forebrain, immunostaining showed a large reduction in TrkA, TrkB and TrkC expression in AD [176], whereas *in situ* hybridization showed no change in TrkB [24]. In parietal cortex mRNA of TrkB

was reported as unchanged whereas TrkA was reduced to less than 50% of normal value [90]. However, Western blotting showed a selective reduction of TrkB catalytic form (145 kDa), not the truncated form, in both frontal and temporal cortex [6], with blots showing a preponderance of truncated over catalytic form of TrkB. Interestingly, studies on PS1 knockouts have shown that the maturation of TrkB and BDNF-inducible TrkB autophosphorylation is compromised in neurones lacking PS1 [148]. The inference here is that mutations in PS1 (as seen in familial AD) may be having an effect on neurotrophin transport.

If there is loss of, or aberrant processing or defective transport of, the Trk receptors in AD or other disease states, this may have important consequences for specific groups of neurones, some being more vulnerable than others.

Huntington's disease

Symptoms and neuropathology

Huntington's disease is an autosomal dominant neurodegenerative disease characterized by a progressive choreic movement disorder. In addition, there are cognitive abnormalities and emotional disturbance, with symptoms often beginning in mid-adulthood. Neuropathology includes the loss of neurones particularly from the striatum and cerebral cortex. In the striatum there is selective degeneration of medium-sized spiny projection neurones [51,163,206] (Figure 5). The protein huntingtin is central to the pathogenesis of this disease, in which huntingtin is mutated by the presence of a polyglutamine expansion at the N-terminus [152]. It is a large cytoplasmic protein (over 3140 amino acids) and is highly expressed in the brain. In almost every case, proteins with repeats of fewer than 38 glutamine residues are harmless, but those with repeats of more than 41 glutamine residues form toxic neuronal nuclear aggregates in the affected neurones, and it has been shown that exon I of the *huntingtin* gene, with an expanded CAG repeat, is sufficient to cause a progressive neurological phenotype in transgenic mice [15].

Protective effects in animal models

The striatal spiny neurones, so vulnerable in Huntington's disease, require BDNF for survival and differentia-

tion [99,142,205], and BDNF protects the majority of striatal projection neurones from excitotoxin lesions [1,30]. Other trophic factors are able to protect certain subsets of these neurones [1]. Overexpression of wild-type huntingtin protein in cell lines and 'knock-in' transgenic mice leads to increased levels of BDNF mRNA and protein [218]. By contrast it has been shown that mutant huntingtin down-regulates BDNF production [218]: thus a reduction in BDNF expressed was seen in cells lines established from a 'knock-in' mouse where a 109 CAG triplet




Figure 4. Photomicrograph of a human basal forebrain magnocellular, hyperchromic, cholinergic neurone stained using an antibody to the p75^{NTR} receptor. Note perinuclear, dendritic and axonal staining.




Figure 5. Golgi-stained section from human striatum showing a medium-sized spiny neurone. These neurones degenerate in Huntington's disease.

repeat had been inserted into the endogenous mouse *huntingtin* gene. In addition BDNF protein level was reduced in striatum and cortex of transgenic mice overexpressing mutant huntingtin. Most importantly BDNF levels in cortical tissue are reduced by 45% in brains from Huntington's disease patients [218]. Various studies on animal models suggest neurotrophic factors may be of benefit in promoting the survival of striatal neurones. In animals treated with the excitotoxin quinolinic acid, cells genetically engineered to release the neurotrophins BDNF, NT-3, or NT-4/5 were implanted into the striatum. All these neurotrophins were shown to promote the survival of striatal projection neurones, with BDNF being most effective as a survival agent [133,155] and NT-3 most successful at initiating differentiation [154]. Whether this therapeutic potential of the neurotrophins will extend to the clinic remains to be seen.

Parkinson's disease

Overview of symptoms and neuropathology

Parkinson's disease is a slow, progressive disease involving rigidity and tremor of the limbs, postural instability and bradykinesia of the limbs and body. It has a peak onset after the age of 60 years and affects about 1% of people over this age. The motor symptoms of PD are directly related to the loss of pigmented cells in the substantia nigra, a nucleus in the ventral midbrain, and to the reduction of the neurotransmitter dopamine in the striatum. The characteristic hallmark is also the presence of the Lewy body, containing the proteins ubiquitin and alpha-synuclein, within the cytoplasm of dying nerve cells. The neuronal loss has been proposed to occur by the action of free radicals and environmental toxins. Genetic linkages have been found in several families [69,158]; the two best described are *alpha-synuclein* on chromosome 4 and *parkin* on chromosome 6.

Current treatment

Most symptoms arise from a deficiency of dopamine and most anti-Parkinson drugs restore or mimic the actions of dopamine. Most commonly levodopa (Atamet or Sinemet) is given to improve motor symptoms, in combination with carbidopa that inhibits peripheral breakdown. The effects of levodopa are transient, because it does not slow down the continuing loss of dopaminergic cells.

Implantation of dopamine-rich tissue into the striatum aims to replace the lost nigral cells. Possible sources are dopamine-like cells from the patient's adrenal gland or carotid body. The results of such operations have been largely unsuccessful because of the low percentage of dopaminergic cells and low neuronal survival rate. Nigral cells from substantia nigra may be an alternative, possibly from pig brain, and embryonic stem cells implanted in the brains of mice and rats have been shown to transform into dopaminergic cells and connect with nearby brain cells [22].

Another alternative is the use of transplanted embryonic neural tissue. Small open-label (no control group) studies have reported long-term improvement in PD patients [55]. However, the first placebo-controlled study using transplanted embryonic neural tissue reported less successful results, with some transplants producing severe side-effects [67] which have been attributed to some aspects of the protocol used, such as tissue-storage and surgical methods.

Trophic factors

Combination of implants and trophic factors Studies have been carried out on implanted cells and tissue, which suggest that pretreatment of cells with trophic factors may improve cell survival [60,81,134]. In mesencephalic primary cultures, addition of NT-4/5 increases survival of dopaminergic neurones, size of the neuronal soma and the complexity of dendritic branching [191]. NT-4/5 infusions can increase the efficacy of nigral grafts in rat models of PD [81,98]. In addition, BDNF treatment has been shown to increase number of dopaminergic neurones and the release of dopamine in cultures before grafting into rat models [92,187].

GDNF (see Figure 1) is a survival factor for mesencephalic dopaminergic neurones [123]. It is able to improve motor deficits in animal models of PD, lesioned by 6-hydroxydopamine or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [77]. Various methods of administration of GDNF have been employed including use of viral vectors, implantation of cells and protein infusion [112,219]. In cultures of foetal midbrain GDNF increases survival and differentiation of dopaminergic neurones [124,139,208] and promotes cell survival and fibre growth in nigral grafts [76,102,172,183,217]. Beneficial effects have been seen in a combined treatment of BDNF and GDNF on foetal nigral tissue [140,178]. Two studies

showed benefit from chronic delivery of GDNF in nonhuman primates. Kordower and colleagues [112] used a lentiviral vector to transfect the striatum and substantia nigra of Parkinson rhesus monkeys. The infusion was carried out 1 week after MPTP toxicity and therefore it is possible that its effects were partly caused by neuroprotective effects of GDNF. Recently Grondin and colleagues [77] showed that infusion of GDNF into the lateral ventricle or the dorsal putamen in a primate MPTP model of PD reversed a 3-month motor dysfunction. During the first month of treatment both methods produced a marked reduction in bradykinesia and rigidity, and an increased number of nigro-striatal dopaminergic fibres and cell bodies in the substantia nigra.

Clinical trials with GDNF Clinical trials with GDNF are so far only in their early stages. In 1999 a report was made of the *post-mortem* results from a patient given monthly intraventricular GDNF injections for over 1 year [113]. No restoration of dopaminergic cells and no improvement in symptoms were observed. However, side-effects, including nausea and psychiatric symptoms, were reported. The authors suggested that other forms of delivery of GDNF should be explored, and it is possible that, as with administration of NGF in AD, the intraventricular route of administration may not be of most benefit. Recently GDNF was administered directly into the parenchyma of the dorsal putamen via a pump and catheter, in five PD patients. After 1 year of treatment the patients are showing a marked reduction of symptoms with no notable side-effects [70]. These exciting results pave the way for a larger controlled trial of GDNF.

Amyotrophic lateral sclerosis

Symptoms and pathology

The most common form of adult onset motor neurone disease is amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease). ALS is a condition in which motor neurones in the spinal cord, brain stem and motor cortex progressively die. The symptoms, limb and bulbar muscle weakness, usually begin in early to mid-50s and rapidly progress towards paralysis and eventual death, usually within 3–5 years of diagnosis. About 30 000 people suffer from this in the USA, and approximately 5–10% of cases are familial. Of the latter, around 20% are caused by dominant mutations in the free-radical-scavenging enzyme, Cu/Zn

superoxide dismutase gene, *SOD1* [166,171], and nearly 100 mutations have now been identified. *SOD1* knockouts are essentially normal [162] but mutant *SOD1* transgenic mice [215] develop adult-onset motor neurone disease with similar neuropathology to human ALS. Riluzole, an antiexcitotoxic agent, extends life by 2–3 months [16,141] and is the major drug approved for treatment. Neuronal loss is accompanied by astrocytosis and the presence of abnormal accumulation of phosphorylated neurofilaments in the cytoplasm [146]. There are many theories as to the mechanism of pathology including oxidative stress, neurofilament abnormalities, aberrant mitochondrial function and glutamate excitotoxicity [41,105,173,174,188]. It is suggested that the neuronal cell death may result from an apoptotic mechanism [115,121,177]. Mitochondrial function is compromised in ALS tissues [135,209] in hybrid cell lines containing mitochondria from ALS patients [195], and in *SOD1* mice [78,100].

Neurotrophins and other trophic factors as therapeutics

Alterations in neurotrophins and their receptors have been found in ALS. In one study in ALS muscle biopsies at *post-mortem* [192], NGF concentrations were 140% higher than normal. In another, mRNA and protein levels of NGF, BDNF, NT-3 and NT-4/5 were all found to be increased [117]. BDNF was strongly up-regulated in the early stage of the disease, whereas levels of NGF, NT-3 and NT-4/5 gradually increased during the course of the disorder. In a study of ALS spinal cords TrkB mRNA was up-regulated [147] but the receptor was found to be much less phosphorylated on tyrosine residues than was that of controls. In an organotypic motor neurone culture model of mitochondrial inhibition [204], NT-4/5 completely prevented malonate-induced toxicity, whereas BDNF or NT-3 had no neuroprotective effect. It was suggested from this that it may be better to explore the use of NT-4/5, as a therapeutic for ALS, than BDNF. Adenovirus-mediated intramuscular gene transfer of NT-3 produced a 50% increase in life span, reduced loss of motor axons and improved neuromuscular function in the mouse mutant pmn (model of progressive motor neuropathy) [79].

However, to date clinical trials have not been particularly successful. In an initial phase I/II, trial BDNF appeared to increase survival rate and retard loss of pulmonary function in ALS patients [28]. These findings were

not replicated, however, in a multicentre placebo-controlled 9-month trial of 1135 ALS patients administered 25 or 100 µg/kg BDNF [196], although the 20% of patients treated with the higher dose did show a nonsignificant trend toward increased survival over a 9-month period. In a later double-blind, sequential, dose-escalation study, recombinant human methionyl BDNF was infused intrathecally for 12 weeks, by means of an implanted pump, into 25 patients with ALS (25–1000 µg/day). The majority of patients reported only mild sensory symptoms usually confined to the lower limbs, which mostly declined or disappeared over several weeks. However, the small number of patients did not allow conclusions to be drawn about the efficacy of the treatment [150], although from the results it would seem that BDNF can be given safely by this method.

Peripheral neuropathy

Causes, symptoms and current therapy

Peripheral neuropathy encompasses a range of neurological disorders resulting from damage to the peripheral nerves. The most common cause is diabetes, in which symptoms are predominantly related to the degeneration of sensory fibres and include numbness, paresthesiae and limb pain, as well as weakness because of motor fibre involvement. In general, drugs are of limited benefit.

NGF implicated in neuropathy and replacement in animal models

NGF is trophic for small fibre sensory and sympathetic neurones, which are known to be affected at an early stage in diabetes. Over two decades ago, changes in retrograde transport of NGF were reported in streptozotocin (STZ)-induced diabetes in rats [101], a model of diabetic neuropathy. In the early 1990s, evidence began to accumulate of an involvement of NGF in diabetic neuropathy. Serum levels of NGF in patients with diabetic neuropathy were found to be lower than in controls, the reduction in NGF levels correlating with the decrease of motor nerve conduction velocity [62]. In rats with STZ-induced sensory neuropathy, NGF levels were doubled in most peripheral targets, perhaps reflecting impaired removal, whereas levels were decreased to roughly half in sympathetic ganglia [89]. Experiments showed that in young diabetics there was an early dysfunction of small-diameter sensory fibres, with

depletion of skin NGF and the sensory neuropeptide, substance P [8]. In rodent models of diabetes, deficits in NGF and TrkA were reported, presumably resulting in decreased support of NGF-dependent sensory neurones [199]. Treatment with exogenous NGF normalized these deficits [200]. In a rat model of hypoinsulinaemic diabetes, sensory and motor conduction velocities are significantly reduced at 7 months, indicative of a polyneuropathy. However administration of NGF (subcutaneous 1 mg/kg, 3 × week) was able to restore the diabetes-related deficit in sensory C-fibre function [58].

In cancer patients, NGF plasma levels were shown to decrease dramatically during chemotherapy. The decrease in NGF levels seemed to correlate with the severity of neurotoxicity and suggested that NGF might prevent antineoplastic drug-induced neuropathies [54]. Gene transfer of herpes simplex virus vector, expressing NGF, into the DRG of mice with STZ-induced sensory neuropathy [74] protected against visible measurements of neuropathy.

Studies in animal models have suggested that NT-3 may also be useful therapeutically in several neuropathies. NT-3 mRNA was found to be deficient in leg muscle of diabetic rats [199] and administration of rhNT-3 was able to restore conduction velocity [200]. Furthermore, intramuscular injection of a recombinant adenovirus encoding NT-3 to deliver sustained low doses of NT-3 [159] prevented or partially prevented the slowing of motor and sensory nerve conduction velocities in STZ-induced diabetes and acrylamide experimental neuropathy.

More recently, with the new interest in pro-NGF, the levels of NGF in diabetes have been re-examined. In a study of human and rat skin and nerve extracts [216], using Western blotting, prepro-NGF was seen to be markedly reduced in skin extracts from patients with subclinical diabetic neuropathy. The overall results of the study suggested that prepro-NGF may be preferentially taken up and transported by p75^{NTR}.

Neurotrophin trials

In the mid-1990s the large-scale production of NGF and other trophic factors made therapeutic trials feasible for various neurodegenerative disorders [170]. Initial Phase I clinical studies in humans indicated that rhNGF produced mild to moderate myalgias shortly following single intravenous or subcutaneous doses of 1 µg/kg; in general, these effects were not observed at lower doses. Following multiple dosing, some patients with peripheral neuropathies

reported an improvement in clinical symptoms, which in some cases correlated with improvement on neurological examinations [10]. Overall, rhNGF was given to 250 patients with diabetic polyneuropathy for 6 months with significant improvement in sensory tests. The impression of most subjects was that their neuropathy had improved. The treatment was well tolerated, with injection site discomfort reported as the most frequent adverse event.

Subsequently, rhNGF was tested in a phase II trial of 270 patients with HIV-associated sensory neuropathy within a multicentre, placebo-controlled, randomized trial [125]. Subcutaneous injection of 1 µg/kg, or 0.3 µg/kg rhNGF twice weekly was given for 18 weeks. Both doses produced significant relief of pain. Long-term evaluation (48 weeks) [179] in an open-label study of 200 subjects with HIV-associated neuropathy gave similar results, confirming that NGF was safe, well-tolerated and significantly reduced pain, although no improvement was reported in sensory function or epidermal nerve fibre density. This led to a phase III trial lasting 48 weeks, in which 1019 patients received rhNGF or placebo. Unfortunately the earlier suggestion of efficacy was not replicated. This was blamed on a variety of differences between the phase II and III trials. However, the end result was that Genentech, the producer of the rhNGF, decided not to proceed further with clinical trials [9].

Neurotrophin agonists/antagonists as therapeutic agents

The pharmacokinetic properties of the neurotrophins are probably the key factor in the therapeutic success or failure of these proteins. The production of small molecule agonists would help to circumvent this problem. Until now the production of such drugs has required the mass screening of large libraries of synthetic chemicals. However, recently small molecule mimetics have been designed which are able to act at the erythropoietin receptor [73]. This has been achieved largely through a detailed knowledge of the interactions between erythropoietin with its receptor. Like NGF, erythropoietin dimerizes two receptors to induce signal transduction. The general principle used was to identify a compound that would bind to one receptor, thereby acting as an antagonist, and to then synthesize that molecule in an oligomeric form such that it was able to bind to two receptors, induce dimerization and initiate signal transduction [160]. Similarly, a small molecule has been

shown as able to mimic the actions of the protein granulocyte colony stimulating factor [198].

Examinations of the structures of the NGF-TrkA Ig2 and NT-4/5- and BDNF-TrkB Ig2 complexes (Figures 3 and 6) show that the Ig2 domains consist of two β -sheets with one exposed disulphide bond. Two contact regions between each receptor domain and the neurotrophin have been identified. One of these comprises residues from the central β -sheet of NGF in contact with the loops at the carboxy-terminal pole of the TrkA Ig2 monomer. As many of the amino acids forming these surfaces are conserved between each of the neurotrophins and their Trk receptors, interactions in this region can be termed the 'conserved' patch, with similar contacts for each neurotrophin:Trk receptor pair. The second contact region comprises the N-terminal residues of NGF and the face of one β -sheet of TrkA Ig2. This can be termed the 'specific' contact patch, as amino acids forming these areas vary between both neurotrophins and the Trk receptors. This region will therefore contribute most of the specificity of binding of the neurotrophins with their receptors. If we examine the interactions formed between NGF and TrkA Ig2 (Figure 6A) and NT-4/5 with TrkB Ig2 (Figure 6B), we can see that in the former case there are key residues which contribute to a hydrophobic environment compared with the NT-4/5:TrkB Ig2 interaction, which is more ionic, in particular, the salt bridge between Arg-11 (NT-4/5) and Asp-298 (TrkB Ig2). This is somewhat of an oversimplification but serves to illustrate how the X-ray crystal structures of the Trk-binding domains, in combination with state-of-the-art computing power, will allow the *in silico* screening of very large virtual libraries (of the order of 10^{11} molecules), hopefully to produce useful therapeutic compounds.

Summary

Neurotrophic proteins have been used in clinical trials for neurodegenerative disorders such as AD, PD, Huntington's disease, ALS and peripheral neuropathy. In general, the results of experiments with animal models and many phase I trials looked promising. However, because of poor pharmacokinetic profiles and difficulties in the delivery of proteins into the brain, the initial promise has not been upheld in larger, placebo-controlled trials. Recent breakthroughs from X-ray crystallography of the neurotrophins and their receptors should allow the development of small molecule agonists which will hopefully fulfil the clinical




Figure 6. (A) Stick representation of the N-terminus of NGF (grey) binding to a pocket in the face of the TrkA molecule (purple). At the base of the pocket is a disulphide bond between two opposing strands of the sheet. The amino acids forming the sides of the pocket are Pro-302, Val-294 and Met-296. The main contact from the NGF N-terminal is from the side chain of Ile-6 which sits in and forms hydrophobic contacts. (B) Stick representation of the N-terminus of NT-4/5 (black) binding to a pocket in the face of the TrkB molecule (grey). At the base of the pocket is a disulphide bond between two opposing strands of the sheet. The amino acids forming the sides of the pocket are Pro-304, Thr-296 and Asp-298. The main contact from the NT-4/5 is from Arg-11, which forms a salt bridge with Asp-298. NGF, nerve growth factor; Trk, tyrosine kinase; NT, neurotrophin.

potential of the neurotrophin approach to the treatment of several neurodegenerative diseases.

Acknowledgements

We would like to acknowledge support from Bristol Research into Care of the Elderly (BRACE) and The Wellcome Trust.

References

- 1 Alberch J, Pérez-Navarro E, Canals JM. Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease. *Brain Res Bull* 2002; **57**: 817–22

- 2 Allen SJ. Alzheimer's disease: past, present and future themes. In *Neurobiology of Alzheimer's Disease* 2nd edn. Eds D Dawbarn, SJ Allen. Oxford: Oxford University Press, 2001; 1–32
- 3 Allen SJ, Dawbarn D, MacGowan SH, Wilcock GK, Treanor JJS, Moss TH. A Quantitative morphometric analysis of basal forebrain neurones expressing B-NGF receptors in normal and Alzheimer's disease brains. *Dementia* 1990; **1**: 125–37
- 4 Allen SJ, Dawbarn D, Spillantini MG, Goedert M, Wilcock GK, Moss TH, Semenenko, FM. The distribution of β -nerve growth factor receptors in the human basal forebrain. *J Comp Neurol* 1989; **289**: 626–40
- 5 Allen SJ, MacGowan SH, Treanor JJS, Feeney R, Wilcock GK, Dawbarn D. Normal NGF content in Alzheimer's disease cerebral cortex and hippocampus. *Neurosci Lett* 1991; **131**: 135–9
- 6 Allen SJ, Wilcock GK, Dawbarn D. Profound and selective loss of catalytic TrkB in Alzheimer's Disease. *Biochem Biophys Res Comm* 1999; **264**: 648–51
- 7 Altar CA, Bakhit C. Receptor-mediated transport of human recombinant nerve growth factor from olfactory bulb to forebrain cholinergic nuclei. *Brain Res* 1991; **541**: 82–8
- 8 Anand P, Warner G, Parrett A. Nerve growth factor related small fibre dysfunction in human diabetic polyneuropathy. *Ann Neurol* 1994; **36**: 284A
- 9 Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong what went right and what does the future hold? *Int Rev Neurobiol* 2002; **50**: 393–413
- 10 Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA, Arriata JL, Artalejo FR. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. *Neurology* 1998; **51**: 695–702
- 11 Arriata JL, Artalejo FR. Methodology, results, and quality of clinical trials of tacrine in the treatment of Alzheimer's disease: a systematic review of the literature. *Age Ageing* 1998; **27**: 161–79
- 12 Banfield MJ, Naylor RL, Robertson AGS, Allen SJ, Dawbarn D, Brady RL. Specificity in neurotrophin: Trk-receptor interaction: the crystal structure of TrkB-d5 in complex with neurotrophin-4/5. *Structure* 2001; **9**: 1191–9
- 13 Barde YA, Edgar D, Thoenen H. Purification of a new neurotrophic factor from mammalian brain. *EMBO J* 1982; **1**: 549–53
- 14 Barrett GL, Bartlett PF. The p75 nerve growth factor receptor mediates survival or death depending on the stage of sensory neuron development. *Proc Nat Acad Sci* 1994; **91**: 6501–5
- 15 Bates GP, Mangiarini L, Davies SW. Transgenic mice in the study of polyglutamine repeat expansion diseases. *Brain Pathol* 1988; **8**: 699–714
- 16 Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. The ALS/riluzole Study Group. *New Eng J Med* 1994; **330**: 585–9
- 17 Bentley CA, Lee KF. p75 is important for axon growth and Schwann cell migration during development. *J Neurosci* 2000; **20**: 7706–15
- 18 Berkemeier LR, Ozcelik T, Francke U, Rosenthal A. Human chromosome 19 contains the neurotrophin-5 gene locus and three related genes that may encode novel acidic neurotrophins. *Somat Cell Mol Genet* 1992; **18**: 233–45
- 19 Berkemeier LR, Winslow JW, Kaplan DR, Nikolics K, Goeddel DV, Rosenthal A. Neurotrophin-5: a novel neurotrophic factor that activates trk and trkB. *Neuron* 1991; **7**: 857–66
- 20 Bibel M, Barde YA. Neurotrophin signal transduction in the nervous system. *Genes Dev* 2000; **14**: 2919–57
- 21 Bibel M, Hoppe E, Barde YA. Biochemical and functional interactions between the neurotrophin receptors trk and p75NTR. *EMBO J* 1999; **18**: 616–22
- 22 Bjorklund LM, Sanchez-Pernaute R, Chung S, Andersson T, Chen IY, McNaught KS, Brownell AL, Jenkins BG, Wahlestedt C, Kim KS, Isacson O. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. *Proc Natl Acad Sci* 2002; **99**: 2344–9
- 23 Blesch A, Conner JM, Tuszynski MH. Modulation of neuronal survival and axonal growth *in vivo* by tetracycline-regulated neurotrophin expression. *Gene Ther* 2001; **8**: 954–60
- 24 Boissiere F, Faucheux B, Agid Y, Hirsch EC. Expression of catalytic trkB gene in the striatum and the basal forebrain of patients with Alzheimer's disease: an *in situ* hybridization study. *Neurosci Lett* 1997; **221**: 141–4
- 25 Boissiere F, Faucheux B, Ruberg M, Agid Y, Hirsch EC. Decreased TrkA gene expression in cholinergic neurons of the striatum and basal forebrain of patients with Alzheimer's disease. *Expt Neurol* 1997; **145**: 245–52
- 26 Bothwell M. Functional interactions of neurotrophins and neurotrophin receptors. *Ann Rev Neurosci* 1995; **18**: 223–53
- 27 Bowen DM, Smith CB, White P, Davison AN. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. *Brain* 1976; **99**: 459–96
- 28 Bradley WG. A phase I/II study of recombinant brain-derived neurotrophic in patients with ALS. *Ann Neurol* 1995; **38**: 971 (Abstract)
- 29 Bucker ED. Implantation of tumours in the hind limb field of the embryonic chick and the developmental response of the lumbosacral nervous system. *Anat Rec* 1948; **102**: 369–89
- 30 Canals JM, Checa N, Marco S, Akerud P, Michels A, Perez-Navarro E, Tolosa E, Arenas E, Alberch J. Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area. *J Neurosci* 2001; **21**: 117–24
- 31 Capsoni S, Giannotta S, Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. *Proc Nat Acad Sci* 2002; **99**: 12432–7
- 32 Capsoni S, Ugolini G, Comparini A, Ruberti F, Berardi N, Cattaneo A. Alzheimer-like neurodegeneration in aged anti-nerve growth factor transgenic mice. *Proc Natl Assoc Sci* 2000; **97**: 6826–31
- 33 Carter BD, Kaltschmidt C, Kaltschmidt B, Offenhauser N, Bohm-Matthaei R, Baeuerle PA, Barde YA. Selective activation of NF-kappa B by nerve growth factor through the neurotrophin receptor p75. *Science* 1996; **272**: 542–5
- 34 Casaccia-Bonnel P, Carter BD, Dobrowsky RT, Chao MV. Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75. *Nature* 1996; **383**: 716–9

- 35 Chao MV. The p75 neurotrophin receptor. *J Neurobiol* 1994; **42**: 1373–85
- 36 Chao MV, Bothwell M. Neurotrophins: to cleave or not to cleave. *Neuron* 2002; **33**: 9–12
- 37 Chen KS, Nishimura MC, Broz S. Assessment of learning and memory performance in mice heterozygous for nerve growth factor deletion. *Soc Neurosci Abstract* 1993; **19**: 1963
- 38 Chen KS, Nishimura MC, Spencer S. Learning memory and the basal cholinergic system in aged mice heterozygous for nerve growth factor deletion. *Soc Neurosci Abstract* 1994; **28**: 856
- 39 Chen XQ, Fawcett JR, Rahman YE, Ala TA, Frey II WH. Delivery of nerve growth factor to the brain via the olfactory pathway. *J Alzheimers Dis* 1998; **1**: 35–44
- 40 Clary DO, Reichardt LF. An alternatively spliced form of the nerve growth factor receptor TrkA confers an enhanced response to neurotrophin 3. *Proc Natl Acad Sci* 1994; **91**: 11131–7
- 41 Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. *Nat Rev Neurosci* 2001; **2**: 806–19
- 42 Cohen S. Purification of a nerve growth promoting protein from the mouse submaxillary gland and its neurocytotoxic anti-serum. *Proc Natl Acad Sci* 1960; **46**: 302–11
- 43 Connor B, Young D, Lawlor P. Trk receptor alterations in Alzheimer's disease. *Mol Brain Res* 1996; **42**: 1–17
- 44 Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunow M. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. *Mol Brain Res* 1997; **49**: 71–81
- 45 Cooper JD, Salehi A, Delcroix JD, Howe CL, Belichenko PV, Chua-Couzens J, Kilbridge JF, Carlson EJ, Epstein CJ, Mobley WC. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. *Proc Natl Acad Sci* 2001; **98**: 10439–44
- 46 Crowley C, Spencer SD, Nishimura MC, Chen KS, Pitts-Meek S, Armanini MP, Ling LH, MacMahon SB, Shelton DL, Levinson AD. Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. *Cell* 1994; **76**: 1001–11
- 47 Crutcher KA, Scott SA, Liang S, Everson WV, Weingartner J. Detection of NGF-like activity in human brain tissue: Increased levels in Alzheimer's disease. *J Neurosci* 1993; **13**: 2540–50
- 48 Davies P, Maloney AJF. Selective loss of central cholinergic neurones in Alzheimer's disease. *Lancet* 1976; **II**: 1403
- 49 Dawbarn D, Allen SJ, Semenenko FM. Immunohistochemical localization of α -nerve growth factor receptors in the forebrain of the rat. *Brain Res* 1988; **440**: 185–9
- 50 Dawbarn D, Allen SJ, Semenenko FM. Coexistence of choline acetyltransferase and α -nerve growth factor receptors in the forebrain of the rat. *Neurosci Lett* 1988; **94**: 138–4
- 51 Dawbarn D, De Quidt M, Emson PC. Survival of basal ganglia neuropeptide Y/somatostatin neurons in Huntington's disease. *Brain Res* 1985; **340**: 251–60
- 52 Day-Lollini PA, Stewart GR, Taylor MJ, Johnson RM, Chellman GJ. Hyperplastic changes within the leptomeninges of the rat and monkey in response to chronic intracerebroventricular infusion of nerve growth factor. *Expt Neurol* 1997; **145**: 24–37
- 53 Dechant G, Barde YA. The neurotrophin receptor p75^{NTR}. Novel functions and implications for diseases of the nervous system. *Nat Neurosci* 2001; **5**: 1131–6
- 54 De Santis S, Pace A, Bove L, Cognetti F, Properzi F, Fiore M, Triaca V, Savarese A, Simone MD, Jandolo B, Manzione L, Aloe L. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. *Clin Cancer Res* 2000; **6**: 90–5
- 55 Dunnett SB, Bjorklund A, Lindvall O. Cell therapy in Parkinson's disease – stop or go? *Nat Rev Neurosci* 2001; **2**: 365–9
- 56 Dunnett SB, Whishaw IQ, Jones GH, Bunch ST. Behavioural biochemical and histochemical effects of different neurotoxic amino acids injected into the nucleus basalis magnocellularis of rats. *Neuroscience* 1987; **20**: 653–69
- 57 Eide FF, Vining ER, Eide BL, Zang K, Wang XY, Reichardt LF. Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain-derived neurotrophic factor signalling. *J Neurosci* 1996; **16**: 3123–39
- 58 Elias KA, Cronin MJ, Stewart TA, Carlsen RC. Peripheral neuropathy in transgenic diabetic mice. restoration of C-fiber function with human recombinant nerve growth factor. *Diabetes* 1998; **47**: 1637–42
- 59 Ernfors P, Ibanez CF, Ebendal T, Olson L, Persson H. Molecular cloning and neurotrophic activities of a protein with structural similarities to nerve growth factor: developmental and topographical expression in the brain. *Proc Natl Acad Sci* 1990; **14**: 5454–8
- 60 Espejo M, Cutillas B, Arenas TE, Ambrosio S. Increased survival of dopaminergic neurons in striatal grafts of fetal ventral mesencephalic cells exposed to neurotrophin-3 or glial cell line-derived neurotrophic factor. *Cell Transplant* 2000; **9**: 45–53
- 61 Fahnstock M, Michalski B, Xu B, Coughlin MD. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. *Mol Cell Neurosci* 2001; **18**: 210–20
- 62 Faradji V, Sotelo J. Low serum levels of nerve growth factor in diabetic neuropathy. *Acta Neurol Scand* 1990; **81**: 402–6
- 63 Fischer W, Bjorklund A, Chen K, Gage FH. NGF improves spatial memory in aged rodents as a function of age. *J Neurosci* 1991; **11**: 1889–906
- 64 Fischer W, Sirevaag A, Wiegand SJ, Lindsay RM, Bjorklund A. Reversal of spatial memory impairments in aged rats by nerve growth factor and neurotrophins 3 and 4/5 but not by brain-derived neurotrophic factor. *Proc Natl Acad Sci* 1994; **91**: 8607–11
- 65 Fischer W, Victorin K, Bjorklund A, Williams LR, Varon S, Gage FH. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. *Nature* 1987; **328**: 65–8
- 66 Francke U, de Martinville B, Coussens L, Ullrich A. The human gene for the beta subunit of nerve growth factor is located on the proximal short arm of chromosome 1. *Science* 1983; **222**: 1248–51
- 67 Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidel-

- berg D, Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. *N Engl J Med* 2001; **344**: 710–9
- 68 Gage FH, Armstrong DM, Williams LR, Varon S. Morphological response of axotomized septal neurons to nerve growth factor. *J Comp Neurol* 1988; **269**: 147–55
- 69 Gasser T, Muller-Myhsok B, Wszolek ZK, Oehlmann R, Calne DB, Bonifati V, Bereznaï B, Fabrizio E, Vieregge P, Horstmann RD. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. *Nat Genet* 1998; **18**: 262–5
- 70 Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. *Nat Med* 2003; in press.
- 71 Gnahn H, Hefti F, Heumann R, Schwab ME, Thoenen H. NGF-mediated increase of choline acetyltransferase ChAT in the neonatal rat forebrain: evidence for a physiological role of NGF in the brain? *Brain Res* 1983; **285**: 45–52
- 72 Goedert M, Fine A, Dawbarn D, Wilcock GK, Chao MV. NGF receptor mRNA distribution in human brain: normal levels in basal forebrain in AD. *Mol Brain Res* 1989; **5**: 1–7
- 73 Goldberg J, Jin Q, Ambrose Y, Satoh S, Desharnais J, Capps K, Boger DL. Erythropoietin mimetics derived from solution phase combinatorial libraries. *J Am Chem Soc* 2002; **124**: 544–55
- 74 Goss JR, Goins WF, Lacomis D, Mata M, Glorioso JC, Fink DJ. Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse. *Diabetes* 2002; **51**: 2227–32
- 75 Gotz R, Koster R, Winkler C, Raulf F, Lottspeich F, Schart IM, Thoenen H. Neurotrophin-6 is a new member of the nerve growth factor family. *Nature* 1994; **372**: 266–9
- 76 Granholm A-C, Mott JL, Bowenkamp K, Eken S, Henry S, Hofer BJ, Lapchak PA, Palmer MR, van Horne C, Gerhardt GA. Glial cell line-derived neurotrophic factor improves survival of ventral mesencephalic grafts to the 6-hydroxydopamine lesioned striatum. *Exp Brain Res* 1997; **116**: 29–38
- 77 Grondin R, Zhang Z, Yi A *et al*. Chronic controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. *Brain* 2002; **125**: 2191–201
- 78 Guegan C, Vila M, Rosoklija G, Hays AP, Przedborski S. Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. *J Neurosci* 2001; **21**: 6569–76
- 79 Haase G, Kennel P, Pettmann B, Vigne E, Akli S, Revah F, Schmalbruch H, Kahn A. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. *Nat Med* 1997; **3**: 429–36
- 80 Hallbook F, Ibanez CF, Persson H. Evolutionary studies of the nerve growth factor family reveal a novel member abundantly expressed in *Xenopus* ovary. *Neuron* 1991; **5**: 845–58
- 81 Haque NSK, Hlavin M-L, Fawcett JW, Dunnett SB. The neurotrophin NT4/5, but not NT3, enhances the efficacy of nigral grafts in a rat model of Parkinson's disease. *Brain Res* 1996; **712**: 45–52
- 82 Haroutunian V, Kanof PD, Davis KL. Partial reversal of lesion-induced deficits in cortical cholinergic markers by nerve growth factor. *Brain Res* 1986; **386**: 397–9
- 83 Hartikka J, Hefti F. Development of septal cholinergic neurons in culture: plating density and glial cells modulate effects of NGF on survival, fiber growth and expression of transmitter specific enzymes. *J Neurosci* 1988; **8**: 2967–85
- 84 Hartikka J, Hefti F. Comparison of nerve growth factor effects on development of septum, striatum, and nucleus basalis cholinergic neurons *in vitro*. *J Neurosci Res* 1988; **21**: 352–64
- 85 Hatanaka H, Tsukui H, Nihonmatsu I. Developmental change in nerve growth factor action from induction of choline acetyltransferase to promotion of cell survival in cultured basal forebrain cholinergic neurons from postnatal rats. *Brain Res* 1988; **467**: 85–95
- 86 Hefti F. Nerve growth factor promotes survival of septal cholinergic neurones after fimbrial transections. *J Neurosci* 1986; **6**: 2155–62
- 87 Hefti F, Mash DC. Localisation of nerve growth factor receptors in the normal human brain and in Alzheimer's disease. *Neurobiol Ageing* 1989; **10**: 75–87
- 88 Hefti F, Hartikka J, Eckenstein F, Gnahn H, Heumann R, Schwab M. Nerve growth factor increases choline acetyltransferase but not survival or fiber outgrowth of cultured fetal septal cholinergic neurons. *Neuroscience* 1985; **14**: 55–68
- 89 Hellweg R, Hartung HD. Endogenous levels of nerve growth factor NGF are altered in experimental diabetes mellitus a possible role for NGF in the pathogenesis of diabetic neuropathy. *J Neurosci Res* 1990; **26**: 258–67
- 90 Hock C, Heese K, Hulette C, Rosenberg C, Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. *Arch Neurol* 2000; **57**: 846–51
- 91 Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde YA. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. *EMBO J* 1990; **9**: 2459–64
- 92 Hoglinger GU, Sautter J, Meyer M, Spenger C, Seiler RW, Oertel WH, Widmer HR. Rat ventral mesencephalon grown as solid tissue cultures: Influence of culture time and BDNF treatment on dopamine neuron survival and function. *Brain Res* 1998; **813**: 313–22
- 93 Hogue-Angeletti R, Bradshaw RA. Nerve growth factor from mouse submaxillary gland: amino acid sequence. *Proc Natl Acad Sci* 1971; **68**: 2417
- 94 Hohn A, Leibrock J, Bailey K, Barde YA. Identification and characterization of a novel member of the nerve growth factor/brain-derived neurotrophic factor family. *Nature* 1990; **344**: 339–41
- 95 Holden PH, Asopa V, Robertson AGS, Clarke AR, Tyler S, Bennett GS, Brain SD, Wilcock GK, Allen SJ, Smith SK, Dawbarn D. Immunoglobulin-like domains define the nerve growth factor binding site of the TrkA receptor. *Nature Biotech* 1997; **15**: 668–72
- 96 Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G. Increased expression of the amyloid precursor beta-

- secretase in Alzheimer's disease. *Ann Neurol* 2002; **51**: 783–6
- 97 Huebner K, Isobe M, Chao M, Bothwell M, Ross AH, Finan J, Hoxie JA, Sehgal A, Buck CR, Lanahan A. The nerve growth factor receptor gene is at human chromosome region 17q12–17q22, distal to the chromosome 17 breakpoint in acute leukemias. *Proc Natl Acad Sci* 1986; **83**: 1403–7
- 98 Hynes MA, Poulsen K, Armanini M. Neurotrophin-4/5 is a survival factor for embryonic midbrain dopaminergic neurons in enriched cultures. *J Neurosci Res* 1994; **37**: 144–54
- 99 Ivkovic S, Ehrlich ME. Expression of the striatal DARPP-32/ARPP-21 phenotype in GABAergic neurons requires neurotrophins in vivo and in vitro. *J Neurosci* 1999; **19**: 5409–19
- 100 Jaarsma D, Rognoni F, van Duijn W, Verspaget HW, Haasdijk ED, Holstege JC. CuZn superoxide dismutase SOD1 accumulates in vacuolated mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations. *Acta Neuropathol Berl* 2001; **102**: 293–305
- 101 Jacobsen J, Brimijoin S, Skau K. Retrograde transport of transmitter enzymes in streptozotocin-diabetic rats. *Histochemistry* 1981; **94**: 659–66
- 102 Johansson M, Friedemann M, Hoffer B, Stromberg I. Effects of glial cell line-derived neurotrophic factor on developing and mature ventral mesencephalic grafts in oculo. *Exp Neurol* 1995; **134**: 25–34
- 103 Johnson D, Lanahan A, Buck CR, Johnson D, Lanahan A, Buck CR, Sehgal A, Morgan C, Mercer E, Bothwell M, Chao M. Expression and structure of the human NGF receptor. *Cell* 1986; **47**: 545–54
- 104 Eriksdotter Jonhagen ME, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B, Olson L, Shigeta M, Theodorsson E, Viitanen M, Winblad B, Wahlund LO. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. *Dementia Geriatric Cognitive Disorders* 1998; **9**: 246–57
- 105 Julien JP. Amyotrophic lateral sclerosis. Unfolding the toxicity of the misfolded. *Cell* 2000; **104**: 581–91
- 106 Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. *Curr Opin Neurobiol* 2000; **10**: 381–91
- 107 Klein R, Jing SQ, Nanduri V, O'Rourke E, Barbacid M. The *trk* proto-oncogene encodes a receptor for nerve growth factor. *Cell* 1991; **65**: 189–97
- 108 Klein R, Lamballe F, Bryant S, Barbacid M. The *trkB* tyrosine protein kinase is a receptor for neurotrophin-4. *Neuron* 1992; **8**: 947–56
- 109 Klein R, Nanduri V, Jing SA, Lamballe F, Tapley P, Bryant S, Cordon-Cardo C, Jones KR, Reichardt LF, Barbacid M. The *trkB* tyrosine kinase is a receptor for brain derived neurotrophic factor and neurotrophin-3. *Cell* 1991; **66**: 395–403
- 110 Klein R, Parada LF, Coulier F, Barbacid M. *trkB* a novel protein tyrosine kinase receptor expressed during mouse neuronal development. *EMBO J* 1989; **8**: 3701–9
- 111 Kordower J, Bartus RT, Bothwell M, Schatteman G, Gash DM. Nerve growth factor receptor immunoreactivity in the nonhuman primate *Cebus apella*: distribution morphology and colocalization with cholinergic enzymes. *J Comp Neurol* 1988; **277**: 465–86
- 112 Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Deglon N, Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. *Science* 2000; **290**: 767–73
- 113 Kordower JH, Palfi S, Chen E-Y, Ma SY, Sendera T, Cochran EJ, Mufson EJ, Penn R, Goetz CG, Comella CD. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. *Ann Neurol* 1999; **46**: 419–24
- 114 Korsching S, Auburger G, Heumann R, Korsching S, Auburger G, Heumann R, Scott J, Thoenen H. Levels of nerve growth factor and its mRNA in the central nervous system of the rat correlate with cholinergic innervation. *EMBO J* 1985; **4**: 1389–93
- 115 Kostic V, Jackson-Lewis V, de Bilbao F, Dubois-Dauphin M, Przedborski S. *Bcl-2*: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. *Science* 1997; **277**: 559–62
- 116 Kromer LF. Nerve growth factor treatment after brain injury prevents neuronal death. *Science* 1987; **235**: 214–6
- 117 Kust BM, Copray JC, Brouwer N, Troost D, Boddeke HW. Elevated levels of neurotrophins in human biceps brachii tissue of amyotrophic lateral sclerosis. *Exp Neurol* 2002; **177**: 419–27
- 118 Lamballe F, Klein R, Barbacid M. *trkC* a new member of the *trk* family of tyrosine protein kinases is a receptor for neurotrophin-3. *Cell* 1991; **66**: 967–9
- 119 Leibrock J, Lottspeich F, Hohn A, Hofer M, Hengeler B, Masiakowski P, Thoenen H, Barde YA. Molecular cloning and expression of brain derived neurotrophic factor. *Nature* 1989; **341**: 149–52
- 120 Levi-Montalcini R, Hamburger V. Selecting growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. *J Exp Zool* 1951; **116**: 321–62
- 121 Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ, Olszewski AJ, Stieg PE, Lee JP, Przedborski S, Friedlander RM. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. *Science* 2000; **288**: 335–9
- 122 Liepinsch E, Ilag LL, Otting G, Ibanez CF. NMR structures of the death domain of the p75 neurotrophin receptor. *EMBO J* 1997; **16**: 4999–5005
- 123 Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurones. *Science* 1993; **260**: 1130–2
- 124 Lin L-FH, Zhang TJ, Collins F, Armes LG. Purification and initial characterization of rat B49 glial cell line-derived neurotrophic factor. *J Neurochem* 1994; **63**: 758–68
- 125 McArthur JC, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra C, Rubin M, Cohen BA, Tucker T, Navia BA, Schifitto G, Katzenstein D, Rask C, Zaboriski L, Smith ME, Shriver S, Millar L, Clifford DB, Karalnik IJ. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. *Neurology* 2000; **54**: 1080–8

- 126 Maisonnier PC, Belluscio L, Friedman B, Alderson RF, Wiegand SJ, Furth ME, Lindsay RM, Yancopoulos GD. NT-3 BDNF and NGF in the developing rat nervous system: parallel as well as reciprocal patterns of expression. *Neuron* 1990; **5**: 501–9
- 127 Maisonnier PC, Belluscio L, Squinto S, Ip NY, Furth ME, Lindsay RM, Yancopoulos GD. Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. *Science* 1990; **247**: 1446–51
- 128 Maisonnier PC, Le Beau MM, Espinosa R III, Ip NY, Belluscio L, de la Monte SM, Squinto S, Furth ME, Yancopoulos GD. Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. *Genomics* 1991; **10**: 558–68
- 129 Mandel R, Gage FH, Thal LJ. Spatial learning in rats: correlation with cortical choline acetyltransferase and improvement with NGF following NBM damage. *Exp Neurol* 1989; **104**: 208–17
- 130 Martin-Zanca D, Hughes SH, Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. *Nature* 1986; **319**: 743–8
- 131 Martin-Zanca D, Oskam R, Mitra G, Copeland T, Barbacid M. Molecular and biochemical characterisation of the human *trk* proto-oncogene. *Mol Cell Biol* 1989; **9**: 24–33
- 132 Martinez HJ, Dreyfus CF, Jonkait GM, Black IB. Nerve growth factor selectively increases cholinergic markers but not neuropeptides in rat basal forebrain culture. *Brain Res* 1987; **412**: 295–301
- 133 Martinez-Serrano A, Bjorklund A. Immortalized neural progenitor cells for CNS gene transfer and repair. *Trends Neurosci* 1997; **20**: 530–8
- 134 Mendez I, Dagher A, Hong M, Hebb A, Gaudet P, Law A, Weerasinghe S, King D, Desrosiers J, Darvesh S, Acorn T, Robertson H. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. *J Neurosurg* 2000; **92**: 863–9
- 135 Menzies FM, Ince PG, Shaw PJ. Mitochondrial involvement in amyotrophic lateral sclerosis. *Neurochem Int* 2002; **40**: 543–51
- 136 Merlio J-P, Ernfors P, Jaber M, Persson H. Molecular cloning of rat *trkC* and identification of cells expressing mRNAs for members of the *trk* family in the rat central nervous system. *Neuroscience* 1992; **51**: 513–32
- 137 Mesulam MM, Geula C. Nucleus basalis Ch4 and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. *J Comp Neurol* 1988; **275**: 219–40
- 138 Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain. cytochemistry and cortical connections of the septal area diagonal band nuclei nucleus basalis substantia innominata and hypothalamus in the rhesus monkey. *J Comp Neurol* 1983; **214**: 170–97
- 139 Meyer M, Johansen J, Gramsbergen JBG, Johansen TE, Zimmer J. Improved survival of embryonic porcine dopaminergic neurons in co-culture with a conditionally immortalized GDNF-producing cell line. *Exp Neurol* 2000; **164**: 82–93
- 140 Meyer M, Matarredona ER, Seiler RW, Zimmer J, Widmer HR. Additive effect of glial cell line-derived neurotrophic factor and neurotrophin-4/5 on rat fetal nigral explant cultures. *Neuroscience* 2001; **108**: 273–84
- 141 Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis ALS/motor neuron disease MND. *Cochrane Database Syst Rev* 2001; CD001447
- 142 Mizuno K, Carnahan J, Nawa H. Brain-derived neurotrophic factor promotes differentiation of striatal GABAergic neurons. *Dev Biol* 1994; **165**: 243–56
- 143 Mufson EJ, Bothwell M, Kordower JH. Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: a quantitative analysis across sub-regions of the basal forebrain. *Exp Neurol* 1989; **105**: 221–32
- 144 Mufson EJ, Kroin JS, Sendera TJ, Sobrieviela T. Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. *Prog Neurobiol* 1999; **57**: 451–84
- 145 Mufson EJ, Lavine N, Jaffar S, Kordower JH, Quirion R, Saragovi HU. Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease. *Expt Neurol* 1997; **146**: 91–103
- 146 Munoz DG, Greene C, Perl P, Selkoe DJ. Accumulation of phosphorylated neurofilaments in anterior horn motoneurons of amyotrophic lateral sclerosis patients. *J Neuropathol Exp Neurol* 1988; **47**: 9–18
- 147 Mutoh T, Sobue G, Hamano T, Kuriyama M, Hirayama M, Yamamoto M, Mitsuma T. Decreased phosphorylation levels of TrkB neurotrophin receptor in the spinal cords from patients with amyotrophic lateral sclerosis. *Neurochem Res* 2000; **25**: 239–45
- 148 Naruse S, Thinakaran G, Luo JJ. Effects of PS1 deficiency on membrane protein trafficking in neurons. *Neuron* 1998; **21**: 1213–21
- 149 Naylor RL, Robertson AGS, Allen SJ, Sessions RB, Clarke AR, Mason GG, Burstyn JJ, Tyler SJ, Wilcock GK, Dawbarn D. A discrete domain of the human TrkB receptor defines the binding sites for brain derived neurotrophic factor and neurotrophin-4. *Biochem Biophys Res Comm* 2002; **291**: 501–7
- 150 Ochs G, Penn RD, York M, Giess R, Beck M, Tonn J, Haigh J, Malta E, Traub M, Sendtner M, Toyka KV. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord* 2000; **1**: 201–6
- 151 Olson L, Nordberg A, Vonholst H, Backman L, Ebendal T, Alafuzoff I, Amberla K, Hartvig P, Herlitz A, Lilja A. Nerve growth-factor affects C-11 nicotine binding blood-flow EEG and verbal episodic memory in an Alzheimer patient. *J Neural Transm* 1992; **4**: 79–95
- 152 Orr H. Beyond the Qs in the polyglutamine diseases. *Genes Dev* 2001; **15**: 925–32
- 153 Perez P, Coll PM, Hempstead BL. NGF binding to the *trk* tyrosine kinase receptor requires the extracellular immunoglobulin-like domains. *Mol Cell Neurosci* 1995; **6**: 97–105

- 154 Perez-Navarro E, Alberch J, Neveu I, Arenas E. Brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4/5 differentially regulate the phenotype and prevent degenerative changes in striatal projection neurons after excitotoxicity in vivo. *Neuroscience* 1999; **91**: 257–64
- 155 Perez-Navarro E, Canudas AM, Akerund P, Alberch J, Arenas E. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease. *J Neurochem* 2000; **75**: 2190–9
- 156 Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE. Neurotransmitter enzyme abnormalities in senile dementia Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. *J Neurol Sci* 1977; **34**: 247–65
- 157 Phillips HS, Hains JM, Armanini M, Laramée GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. *Neuron* 1991; **7**: 695–702
- 158 Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G, Sanges G, Stenroos ES, Pho LT, Schaffer AA, Lazzarini AM, Nussbaum RL, Duvoisin RC. Mapping of a gene for Parkinson's disease to chromosome 4q21–q23. *Science* 1996; **274**: 1197–9
- 159 Pradat PF, Kennel P, Naimi-Sadaoui S, Finiels F, Orsini C, Revah F, Delaere P, Mallet J. Continuous delivery of neurotrophin 3 by gene therapy has a neuroprotective effect in experimental models of diabetic and acrylamide neuropathies. *Hum Gene Ther* 2001; **12**: 2237–49
- 160 Qureshi SA, Kim RM, Konteatis Z, Biazzo DE, Motamedi H, Rodrigues R, Boice JA, Calaycay JR, Bednarek MA, Griffin P, Gao YD, Chapman K, Mark DF. Mimicry of erythropoietin by a nonpeptide molecule. *Proc Natl Acad Sci* 1999; **96**: 12156–61
- 161 Radeke MJ, Misko TP, Hsu C, Herzenberg LA, Shooter EM. Gene transfer and molecular cloning on the rat nerve growth factor receptor. *Nature* 1987; **325**: 593–7
- 162 Reaume AG, Elliott JL, Hoffman EK, Kowall NW, Ferrante RJ, Siwek DF, Wilcox HM, Flood DG, Beal MF, Brown RH Jr, Scott RW, Snider WD. Motor neurones in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. *Nat Genet* 1996; **13**: 43–7
- 163 Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. *Proc Nat Acad Sci* 1988; **85**: 5733–7
- 164 Ridley RM, Murray TK, Johnson JA, Baker HF. Learning impairment following lesion of the basal nucleus of marmoset: modification by cholinergic drugs. *Brain Res* 1986; **376**: 108–16
- 165 Riopelle J, Richardson PM, Verge VM. Distribution and characteristics of nerve growth factor binding on cholinergic neurons of rat and monkey forebrain. *Neurochem Res* 1987; **12**: 923–8
- 166 Robberecht W. Genetics of amyotrophic lateral sclerosis. *J Neurol* 2000; **247**: S6, VI/2–6
- 167 Robertson AGS, Banfield MJ, Allen SJ, Dando JA, Mason GG, Tyler SJ, Bennett GS, Brain SD, Clarke AR, Naylor RL, Wilcock GK, Brady RL, Dawbarn D. Identification and structure of the nerve growth factor binding site on TrkA. *Biochem Biophys Res Comm* 2001; **282**: 131–41
- 168 Robinson RC, Radziejewski C, Stuart DI, Jones EY. Structure of the brain-derived neurotrophic factor/neurotrophin 3 heterodimer. *Biochemistry* 1995; **34**: 4139–46
- 169 Rodriguez-Tebar A, Dechant G, Barde YA. Binding of brain derived neurotrophic factor to the nerve growth factor receptor. *Neuron* 1990; **4**: 487–92
- 170 Rogers BC. Development of recombinant human nerve growth factor rhNGF as a treatment for peripheral neuropathic disease. *Neurotoxicology* 1996; **17**: 865–70
- 171 Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentali A, Donaldson D, Goto J, O'Regan JP, Deng HX. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. *Nature* 1993; **362**: 59–62
- 172 Rosenblad C, Martinez-Serrano A, Bjorklund A. Glial cell line-derived neurotrophic factor increases survival growth and function of intrastriatal fetal nigral dopaminergic grafts. *Neuroscience* 1996; **75**: 979–85
- 173 Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. *Ann Neurol* 1995; **38**: 73–84
- 174 Rowland LP, Scheider LA. Amyotrophic lateral sclerosis. *N Engl J Med* 2001; **344**: 1688–700
- 175 Ruberti F, Capsoni S, Comparini A, Di Daniel E, Franzot J, Gonfloni S, Rossi G, Berardi N, Cattaneo A. Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy. *J Neurosci* 2000; **20**: 2589–601
- 176 Salehi A, Verhaagen J, Dijkhuizen PA, Swaab DF. Co-localization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer's disease. *Neuroscience* 1996; **75**: 373–87
- 177 Sathasivam S, Ince PG, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. *Neuropath Appl Neurobiol* 2001; **27**: 257–74
- 178 Sautter J, Meyer M, Spenger C, Seiler RW, Widmer HR. Effects of combined BDNF and GDNF treatment on cultured dopaminergic midbrain neurons. *Neuroreport* 1998; **9**: 1093–6
- 179 Schifitto G, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra CM, Rubin M, Cohen BA, Tucker T, Koranik IJ, Katzenstein D, Haidich B, Smith ME, Shriver S, Millar L, Clifford DB, McArthur JC. Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. *Neurology* 2001; **57**: 1313–6
- 180 Schneider R, Schweigwer A. A novel modular mosaic of cell adhesion motifs in the extracellular domains of the neurogenic trk and trkB tyrosine kinase receptors. *Oncogene* 1991; **6**: 1807–11
- 181 Seiler M, Schwab ME. Specific retrograde transport of nerve growth factor NGF from neocortex to nucleus basalis in the rat. *Brain Res* 1984; **300**: 33–9
- 182 Shelton DL, Sutherland J, Gripp J, Camerato T, Armanini MP, Phillips HS, Carroll K, Spencer SD, Levinson AD. Human trks: molecular cloning tissue distribution and

- expression of extracellular domain immunoadhesins. *J Neurosci* 1995; **15**: 477–91
- 183 Sinclair SR, Svendsen CN, Torres EM, Martin D, Fawcett JW, Dunnett SB. GDNF enhances dopaminergic cell survival and fibre outgrowth in embryonic nigral grafts. *Neuroreport* 1996; **7**: 2547–52
- 184 Smeyne RJ, Klein R, Schnapp A, Long LK, Bryant S, Lewin A, Lira SA, Barbacid M. Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. *Nature* 1994; **368**: 246–9
- 185 Smith DE, Roberts J, Gage FH, Tuszynski MH. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. *Proc Natl Acad Sci* 1999; **96**: 10893–8
- 186 Sobreviela T, Clary DO, Reichardt LF, Brandabur MM, Kordower JH, Mufson EJ. TrkA-immunoreactive profiles in the central nervous system: colocalization with neurons containing p75 nerve growth factor receptor choline acetyltransferase and serotonin. *J Comp Neurol* 1994; **350**: 587–611
- 187 Spenger C, Hyman C, Studer L, Egli M, Evtouchenko L, Jackson C, Dahl-Jorgensen A, Lindsay RM, Seiler RW. Effects of BDNF on dopaminergic serotonergic and GABAergic neurons in cultures of human fetal ventral mesencephalon. *Exp Neurol* 1995; **133**: 50–63
- 188 Spreux-Varoquaux O, Bensimon G, Lacomblez L, Pradat PF, Le Forestier N, Marouan A, Dib M, Meininger V. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. *J Neurol Sci* 2002; **193**: 73–8
- 189 Steininger TL, Wainer BH, Klein R, Steininger TL, Wainer BH, Klein R, Barbacid M, Palfrey HC. High-affinity nerve growth factor receptor Trk immunoreactivity is localized in cholinergic neurons of the basal forebrain and striatum in the adult rat brain. *Brain Res* 1993; **612**: 331–5
- 190 Strohmaier C, Carter BD, Urfer R, Barde YA, Dechant GA. A splice variant of the neurotrophin receptor trkB with increased specificity for brain-derived neurotrophic factor. *EMBO J* 1996; **15**: 3332–7
- 191 Studer L, Spenger C, Seiler RW, Altar CA, Lindsay RM, Hyman C. Comparison of the effects of the neurotrophins on the morphological structure of dopaminergic neurons in cultures of rat substantia nigra. *Eur J Neurosci* 1995; **7**: 223–33
- 192 Stuerenburg HJ, Kunze K. Tissue nerve growth factor concentrations in neuromuscular diseases. *Eur J Neurol* 1998; **5**: 487–90
- 193 Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia Alzheimer type. *New Engl J Med* 1986; **315**: 1241–5
- 194 Sutter A, Riopelle RJ, Harris-Warrick RM, Shooter EM. Characterisation of two distinct classes of binding sites on chick embryo sensory ganglia cells. *J Biol Chem* 1979; **254**: 5972–892
- 195 Swerdlow RH, Parks JK, Cassarino DS, Trimmer PA, Miller SW, Maguire DJ, Sheehan JP, Maguire RS, Pattee G, Juel VC, Phillips LH, Tuttle JB, Bennett JP Jr, Davis RE, Parker WD Jr. Mitochondria in sporadic amyotrophic lateral sclerosis. *Exp Neurol* 1998; **153**: 135–42
- 196 The BDNF Study Group Phase III. A controlled trial of recombinant methionyl human BDNF in ALS. *Neurology* 1999; **52**: 1427–33
- 197 Thorne RG, Frey WH. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. *Clin Pharmacokinet* 2001; **40**: 907–46
- 198 Tian SS, Lamb P, King AG, Miller SG, Kessler L, Luengo JJ, Averill L, Johnson RK, Gleason JG, Pelus LM, Dillon SB, Rosen J. A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor. *Science* 1998; **281**: 257–9
- 199 Tomlinson DR, Fernyhough P, Diemel LT. Neurotrophins and peripheral neuropathy. *Phil Trans R Soc Lond B Biol Sci* 1996; **351**: 455–62
- 200 Tomlinson DR, Fernyhough P, Diemel LT. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors. *Diabetes* 1997; **46**: S43–9
- 201 Treanor JJS, Dawbarn D, Allen SJ, MacGowan SH, Wilcock GK. Nerve growth factor receptor binding in normal and Alzheimer's disease basal forebrain. *Neurosci Lett* 1991; **121**: 73–6
- 202 Tyler SJ, Dawbarn D, Wilcock GK, Allen SJ. Alpha- and beta-secretase: profound changes in Alzheimer's disease. *Biochem Biophys Res Commun* 2002; **239**: 373–6
- 203 Ultsch MH, Wiesmann C, Simmons LC, Henrich J, Yang M, Reilly D, Bass SH, de Vos AM. Crystal Structures of the Neurotrophin-binding Domain of TrkA TrkB and TrkC. *J Mol Biol* 1999; **290**: 149–59
- 204 Van Westerlaak MG, Bar PR, Cools AR, Joosten EA. Malonate-induced cortico-motoneuron death is attenuated by NT-4 but not by BDNF or NT-3. *Neuroreport* 2001; **12**: 1355–8
- 205 Ventimiglia R, Mather P, Jones BE, Lindsay RM. The neurotrophins BDNF, NT-3 & NT-4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro. *Eur J Neurosci* 1995; **7**: 213–22
- 206 Vonsattel JP, DiFiglia M. Huntington disease. *J Neurop Exper Neurol* 1988; **57**: 369–84
- 207 Walsh GS, Krol KM, Crutcher KA, Kawaja MD. Enhanced neurotrophin induced axon growth in myelinated portions of the CNS in mice lacking the p75 neurotrophin receptor. *J Neurosci* 1999; **19**: 4155–68
- 208 Widmer HR, Schaller B, Meyer M, Seiler RW. Glial cell line-derived neurotrophic factor stimulates the morphological differentiation of cultured nigral calbindin and calretinin expressing neurons. *Exp Neurol* 2000; **164**: 71–81
- 209 Wiedemann FR, Manfredi G, Mawrin C, Wiedemann FR, Manfredi G, Mawrin C, Beal MF, Schon EA. Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. *J Neurochem* 2002; **80**: 616–25
- 210 Wiesmann C, Ultsch MH, Bass SH, de Vos AM. Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor. *Nature* 1999; **401**: 184–8
- 211 Wilcock GK, Esiri MM, Bowen DM, Hughes AO. The differential involvement of subcortical nuclei in senile dementia of the Alzheimer type. *J Neurol Neurosurg Psychiatry* 1988; **51**: 842–9

- 212 Will B, Hefti F. Behavioral and neurochemical effects of chronic intraventricular-injections of nerve growth-factor in adult-rats with fimbria lesions. *Behav Brain Res* 1985; **17**: 17–24
- 213 Williams LR, Varon S, Peterson, Victorin K, Fischer W, Bjorklund A, Gage FH. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transaction. *Proc Natl Acad Sci* 1986; **83**: 9231–5
- 214 Winkler J, Ramirez GA, Kuhn HG, Peterson DA, Day-Lollini PA, Stewart GR, Tuszynski MH, Gage FH, Thal LJ. Reversible schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor. *Ann Neurol* 1997; **41**: 82–93
- 215 Wong PC, Cai H, Borchelt DR, Price DL. Genetically engineered models relevant to neurodegenerative disorders: their value for understanding disease mechanisms and designing/testing experimental therapeutics. *J Mol Neurosci* 2001; **17**: 233–57
- 216 Yiangou Y, Facer P, Sinicropi DV, Boucher TJ, Bennett DL, McMahon SB, Anand P. Molecular forms of NGF in human and rat neuropathic tissues: decreased NGF precursor-like immunoreactivity in human diabetic skin. *J Periph Nerv Syst* 2002; **7**: 190–7
- 217 Yurek DM. Glial cell line-derived neurotrophic factor improves survival of dopaminergic neurons in transplants of fetal ventral mesencephalic tissue. *Exp Neurol* 1998; **153**: 195–202
- 218 Zuccato A, Ciammola D, Rigamonti BR, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E. Loss of Huntingtin-mediated BDNF gene transcription in Huntington's disease. *Science* 2001; **293**: 493–8
- 219 Zurn AD, Henry H, Schlupe M, Aubert V, Winkel L, Eilers B, Bachmann C, Aebischer. Evaluation of an intrathecal immune response in amyotrophic lateral sclerosis patients implanted with encapsulated genetically engineered xenogeneic cells. *Cell Transplant* 2000; **9**: 471–84

Received 13 January 2003

Accepted after revision 16 April 2003